HRP20210819T1 - Fenfluramin za uporabu u liječenju dravet sindroma - Google Patents
Fenfluramin za uporabu u liječenju dravet sindroma Download PDFInfo
- Publication number
- HRP20210819T1 HRP20210819T1 HRP20210819TT HRP20210819T HRP20210819T1 HR P20210819 T1 HRP20210819 T1 HR P20210819T1 HR P20210819T T HRP20210819T T HR P20210819TT HR P20210819 T HRP20210819 T HR P20210819T HR P20210819 T1 HRP20210819 T1 HR P20210819T1
- Authority
- HR
- Croatia
- Prior art keywords
- fenfluramine
- treatment
- dravet syndrome
- formulation
- scn1
- Prior art date
Links
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 title claims 4
- 229960001582 fenfluramine Drugs 0.000 title claims 4
- 201000007547 Dravet syndrome Diseases 0.000 title claims 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 title claims 3
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 title claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims 2
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims 2
- 102000017706 GABRD Human genes 0.000 claims 1
- 102000017703 GABRG2 Human genes 0.000 claims 1
- 101001073587 Homo sapiens Gamma-aminobutyric acid receptor subunit delta Proteins 0.000 claims 1
- 101000926813 Homo sapiens Gamma-aminobutyric acid receptor subunit gamma-2 Proteins 0.000 claims 1
- 101001072243 Homo sapiens Protocadherin-19 Proteins 0.000 claims 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims 1
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 claims 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims 1
- 102100036389 Protocadherin-19 Human genes 0.000 claims 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims 1
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 claims 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/887,014 US9549909B2 (en) | 2013-05-03 | 2013-05-03 | Method for the treatment of dravet syndrome |
| EP18152406.7A EP3329909B1 (en) | 2013-05-03 | 2014-05-01 | Fenfluramine for use in the treatment of dravet syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210819T1 true HRP20210819T1 (hr) | 2021-08-20 |
Family
ID=50729472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210819TT HRP20210819T1 (hr) | 2013-05-03 | 2021-05-21 | Fenfluramin za uporabu u liječenju dravet sindroma |
Country Status (17)
| Country | Link |
|---|---|
| US (13) | US9549909B2 (enExample) |
| EP (2) | EP3329909B1 (enExample) |
| JP (3) | JP6441313B2 (enExample) |
| AU (4) | AU2014261329B2 (enExample) |
| BR (1) | BR112015027282A8 (enExample) |
| CA (1) | CA2909335C (enExample) |
| CY (1) | CY1124298T1 (enExample) |
| DK (2) | DK2991637T3 (enExample) |
| ES (2) | ES2863929T3 (enExample) |
| HR (1) | HRP20210819T1 (enExample) |
| HU (1) | HUE054577T2 (enExample) |
| LT (1) | LT3329909T (enExample) |
| NO (1) | NO3092234T3 (enExample) |
| PL (2) | PL2991637T3 (enExample) |
| PT (2) | PT2991637T (enExample) |
| SI (1) | SI3329909T1 (enExample) |
| WO (1) | WO2014177676A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| BR112017006219A8 (pt) | 2014-09-29 | 2023-02-14 | Zogenix International Ltd | Sistema de controle para controle de distribuição de medicamentos |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| DK3261640T3 (da) | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| KR102615486B1 (ko) * | 2015-08-24 | 2023-12-19 | 조게닉스 인터내셔널 리미티드 | 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법 |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| CN116059236A (zh) | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| RU2021106383A (ru) * | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US20180092864A1 (en) * | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
| EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| MX2019012285A (es) | 2017-04-13 | 2020-11-06 | Ovid Therapeutics Inc | Metodos de tratamiento de encefalopatias del desarrollo. |
| CA3062247A1 (en) * | 2017-05-09 | 2018-11-15 | Zogenix International Limited | Methods of treating doose syndrome using fenfluramine |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| KR20260009385A (ko) | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| US20190091179A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| US20190125697A1 (en) * | 2017-09-26 | 2019-05-02 | Zogenix International Limited | Method of reduction in convulsive seizure frequency |
| WO2019067413A1 (en) * | 2017-09-26 | 2019-04-04 | Zogenix International Limited | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| US10517841B1 (en) | 2018-06-14 | 2019-12-31 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| WO2020014075A1 (en) * | 2018-07-10 | 2020-01-16 | Zogenix International Limited | Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension |
| BR112021001135A2 (pt) * | 2018-07-27 | 2021-04-20 | Xenon Pharmaceuticals Inc. | compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| WO2020176276A1 (en) * | 2019-02-25 | 2020-09-03 | Zogenix International Limited | A formulation for improving seizure control |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| CN111944835B (zh) * | 2019-05-14 | 2022-03-29 | 南通大学 | 一种突变型gabrg2转基因斑马鱼癫痫模型的构建方法及应用 |
| EP4021454A1 (en) * | 2019-08-30 | 2022-07-06 | Research Institute at Nationwide Children's Hospital | Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction |
| KR20220101610A (ko) * | 2019-09-17 | 2022-07-19 | 조게닉스 인터내셔널 리미티드 | 펜플루라민을 사용하여 간질 환자를 치료하는 방법 |
| US20210299064A1 (en) | 2020-02-05 | 2021-09-30 | Zogenix International Limited | Method of treating patients with lennox-gastaut syndrome |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| GB202009321D0 (en) | 2020-06-18 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US20230165810A1 (en) * | 2021-12-01 | 2023-06-01 | Zogenix International Limited | Fenfluramine for treatment of conditions associated with spreading depolarization |
| CA3264785A1 (en) | 2022-08-12 | 2024-02-15 | Jazz Pharmaceuticals Research Uk Limited | ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| US3117160A (en) | 1961-07-27 | 1964-01-07 | Pfizer & Co C | Aralkylamines |
| US3198834A (en) | 1964-07-27 | 1965-08-03 | Snc Science Union Et Compagnie | Optical isomers of trifluoromethylated phenethylamines |
| GB1254332A (en) | 1969-02-27 | 1971-11-17 | Science Union & Cie | Amino acids and their derivatives and processes for preparing them |
| DE2143204C3 (de) | 1971-08-28 | 1979-09-27 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis |
| DE2150399A1 (de) | 1971-10-09 | 1973-04-12 | Hoechst Ag | Neue oxime |
| GB1413070A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of - norfenfluramine and - fenfluramine and salts thereof |
| GB1413078A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof |
| US4309445A (en) | 1980-06-16 | 1982-01-05 | Massachusetts Institute Of Technology | d-Fenfluramine for modifying feeding behavior |
| US4452815A (en) | 1980-06-16 | 1984-06-05 | Massachusetts Institute Of Technology | Method of utilizing d,l-fenfluramine for modifying feeding behavior |
| DE3717434C1 (de) | 1987-05-23 | 1988-09-15 | Degussa | Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril |
| US4857553A (en) | 1987-08-06 | 1989-08-15 | A. H. Robins Company, Incorporated | Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents |
| KR890003368A (ko) | 1987-08-06 | 1989-04-14 | 원본미기재 | 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법 |
| HU204497B (en) | 1989-10-09 | 1992-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing phenfluramine |
| IT1238686B (it) | 1990-02-09 | 1993-09-01 | Lab Mag Spa | Procedimento per la preparazione di levo e destro fenfluramina |
| FR2663539B1 (fr) | 1990-06-22 | 1994-10-07 | Adir | Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age. |
| FR2684552B1 (fr) | 1991-12-06 | 1995-04-28 | Adir | Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants. |
| FR2685204B1 (fr) | 1991-12-19 | 1995-06-16 | Palmer Research | Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine. |
| US5985880A (en) | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| ES2139750T3 (es) | 1993-08-06 | 2000-02-16 | Upjohn Co | 2-aminoindanos como ligandos selectivos d3 de la dopamina. |
| US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
| US5412102A (en) | 1994-05-27 | 1995-05-02 | Syntex (U.S.A.) Inc. | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid |
| ATE199829T1 (de) | 1994-06-03 | 2001-04-15 | Thejmde Trust | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon |
| IT1298349B1 (it) | 1996-05-29 | 2000-01-05 | Alfa Chem Ital | Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina |
| IT1292885B1 (it) | 1997-04-28 | 1999-02-11 | Alfa Chem Ital | Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina. |
| EP0920864A1 (en) | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US20020098175A1 (en) | 1998-06-16 | 2002-07-25 | Zohoungbogbo Mathias C. | Dietetic food composition and dietetic method using such composition |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| WO2000038672A2 (en) | 1998-12-23 | 2000-07-06 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US20080103179A1 (en) | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US7124031B1 (en) | 2000-05-11 | 2006-10-17 | Medco Health Solutions, Inc. | System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records |
| US20020032581A1 (en) | 2000-07-17 | 2002-03-14 | Reitberg Donald P. | Single-patient drug trials used with accumulated database: risk of habituation |
| US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| JP2004530436A (ja) | 2001-06-22 | 2004-10-07 | ユニべルシテ・カトリック・ドゥ・ルベン | 昆虫の産卵および内部捕食寄生生物の飼養のための人工培地としてのヒドロゲルビーズまたはカプセル |
| EP1411955A4 (en) | 2001-07-31 | 2006-07-05 | Wyeth Corp | SUCRALOSE FORMULATIONS FOR COVERING UNANGEAN TASTE |
| AUPR732601A0 (en) | 2001-08-28 | 2001-09-20 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of amines such as ephedrine and inter mediates |
| ES2320979T3 (es) | 2001-09-24 | 2009-06-01 | Imperial Innovations Limited | Pyy-36 para la reduccion o prevencion de la obesidad. |
| RU2317104C2 (ru) | 2001-09-24 | 2008-02-20 | Импиэриэл Инноувейшнс Лимитид | Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения |
| US6599901B1 (en) | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
| US7668730B2 (en) | 2002-12-17 | 2010-02-23 | JPI Commercial, LLC. | Sensitive drug distribution system and method |
| WO2005004865A1 (en) | 2003-07-08 | 2005-01-20 | Georg-August-Universität Göttingen | Use of 5-ht4(a)-serotonin receptor agonists |
| GB0410266D0 (en) | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| US20050260610A1 (en) | 2004-05-20 | 2005-11-24 | Kurtz Richard E | Method for diagnosing and prescribing a regimen of therapy for human health risk |
| US9820658B2 (en) | 2006-06-30 | 2017-11-21 | Bao Q. Tran | Systems and methods for providing interoperability among healthcare devices |
| US20060079582A1 (en) | 2004-09-23 | 2006-04-13 | Jeffrey Jonas | Memantine for the treatment of childhood behavioral disorders |
| CN100567252C (zh) | 2004-10-11 | 2009-12-09 | 俞锋 | 盐酸芬氟拉明原料药和片剂及其制备方法 |
| EP1863381A4 (en) | 2005-03-21 | 2009-09-09 | Health Smart Ltd | SYSTEM FOR CONTINUOUS BLOOD PRESSURE MONITORING |
| MX2007014713A (es) | 2005-05-25 | 2008-02-14 | Janssen Pharmaceutica Nv | Formulacion pediatrica de topiramato. |
| WO2006133199A2 (en) | 2005-06-06 | 2006-12-14 | University Of South Florida | Treatment with sigma receptor agonists post-stroke |
| US20100088778A1 (en) | 2005-06-16 | 2010-04-08 | John Charles Mulley | Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| WO2007031846A2 (en) | 2005-09-14 | 2007-03-22 | University Of The Witwatersrand, Johannesburg | Pharmaceutical composition |
| CN101583311B (zh) | 2005-09-19 | 2012-06-27 | 比奥莱特有限公司 | 用于检测癫痫事件的装置和方法 |
| US8589175B2 (en) | 2005-11-29 | 2013-11-19 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| EP1971394A4 (en) | 2005-12-28 | 2009-04-01 | Neurovista Corp | METHOD AND SYSTEMS FOR PROPOSING A TREATMENT FOR A PATIENT TO CHECK EPILEPSIA AND OTHER NEUROLOGICAL DISEASES |
| US20090005361A1 (en) | 2006-02-06 | 2009-01-01 | Randy Lee Webb | Combination of Organic Compounds |
| DE102006030113B4 (de) | 2006-06-28 | 2009-02-12 | Chemische Fabrik Budenheim Kg | Graphitfreier Hochtemperatur-Schmierstoff |
| WO2008021954A2 (en) | 2006-08-09 | 2008-02-21 | Biogen Idec Ma Inc. | Method for distribution of a drug |
| BRPI0716375A2 (pt) | 2006-08-31 | 2013-10-15 | Univ Alberta | Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito... |
| EP2115648A2 (en) | 2007-01-31 | 2009-11-11 | Quintiles Transnational Corp., Inc. | Methods and systems for site startup |
| HUE032251T2 (en) | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| EP2125799A1 (en) | 2007-02-28 | 2009-12-02 | Smithkline Beecham Corporation | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
| EP2254577A1 (en) | 2007-12-26 | 2010-12-01 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| WO2010020585A1 (en) | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
| WO2010025931A2 (en) | 2008-09-05 | 2010-03-11 | Grünenthal GmbH | Pharmaceutical combination |
| US8386274B1 (en) | 2008-09-17 | 2013-02-26 | Mckesson Financial Holdings Limited | Systems and methods for a prescription safety network utilizing eligibility verification transactions |
| BRPI0919796A2 (pt) | 2008-10-09 | 2015-12-15 | Acraf | formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável |
| EP2355818A4 (en) | 2008-10-10 | 2012-04-11 | Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res | METHOD AND COMPOSITIONS FOR TREATING THE STATUS EPILEPTICUS AND STATUS EPILEPTICUS CAUSING ATTACHMENTS |
| TWI503101B (zh) | 2008-12-15 | 2015-10-11 | 波提亞斯數位康健公司 | 與身體有關的接收器及其方法 |
| WO2010104841A2 (en) | 2009-03-09 | 2010-09-16 | Celgene Corporation | Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof |
| CA2758774C (en) | 2009-04-15 | 2015-02-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
| US20100324936A1 (en) | 2009-04-22 | 2010-12-23 | Suresh-Kumar Venkata Vishnubhatla | Pharmacy management and administration with bedside real-time medical event data collection |
| US9453027B2 (en) | 2009-07-27 | 2016-09-27 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
| AR079862A1 (es) | 2010-01-08 | 2012-02-22 | Eurand Inc | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion |
| CA2792507C (en) | 2010-03-09 | 2018-05-22 | Perceptimed, Inc. | Medication verification and dispensing |
| WO2011119227A2 (en) | 2010-03-25 | 2011-09-29 | Columbia Northwest Pharmaceuticals, Llc | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients |
| JP2011221623A (ja) | 2010-04-06 | 2011-11-04 | Kakimori Suri | 在宅診療支援システム及び方法 |
| CA2800220C (en) | 2010-05-21 | 2019-04-30 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| EP2399513B1 (en) | 2010-06-23 | 2017-01-04 | Qatar University Qstp-B | System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms |
| US20140162942A1 (en) | 2010-07-30 | 2014-06-12 | Anima Ghosal | Inhibition of cyp3a drug metabolism |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
| RU2541159C2 (ru) | 2010-10-26 | 2015-02-10 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов |
| RU103209U1 (ru) | 2010-10-29 | 2011-03-27 | Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" | Клиническая информационная система |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US10183008B2 (en) | 2011-02-09 | 2019-01-22 | University Of South Carolina | Treatment of prolonged status epilepticus |
| JP5693325B2 (ja) | 2011-03-29 | 2015-04-01 | 小林クリエイト株式会社 | 健診結果出力システム及び健診結果出力プログラム |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| US10092750B2 (en) | 2011-11-11 | 2018-10-09 | Neuroenabling Technologies, Inc. | Transcutaneous neuromodulation system and methods of using same |
| WO2013096878A1 (en) | 2011-12-22 | 2013-06-27 | University Of Idaho | Garcinia buchananii baker compounds, compositions and related methods |
| WO2013112363A1 (en) | 2012-01-27 | 2013-08-01 | Catalyst Pharmaceutical Partners | Method of treating tourette's disorder with gaba-aminotransferase inactivators |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US20130218586A1 (en) | 2012-02-21 | 2013-08-22 | Frederic J. Huser | Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status |
| JP6075973B2 (ja) | 2012-06-04 | 2017-02-08 | 富士通株式会社 | 健康状態判定装置およびその作動方法 |
| BR112015011213A2 (pt) | 2012-11-15 | 2017-08-29 | Galleon Pharmaceuticals Inc | Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. |
| WO2014106825A2 (en) | 2013-01-06 | 2014-07-10 | Jonathan Rabinowitz | Methods and devices for identifying improper medical reporting |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| SI3024463T1 (sl) | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2015077057A1 (en) | 2013-11-20 | 2015-05-28 | Texas Southern University | Methionine aminopeptidase inhibitors for treating infectious diseases |
| CN103886415A (zh) | 2014-03-25 | 2014-06-25 | 北京蝶禾谊安信息技术有限公司 | 药品管理方法和装置 |
| CN106461677B (zh) | 2014-04-22 | 2018-09-11 | 国立大学法人东北大学 | 肺高血压病的检查方法 |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| WO2016003966A1 (en) | 2014-06-30 | 2016-01-07 | University Of Cincinnati | Non-invasive detection of spreading depolarization using scalp electroencephalography |
| BR112017006219A8 (pt) | 2014-09-29 | 2023-02-14 | Zogenix International Ltd | Sistema de controle para controle de distribuição de medicamentos |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| JP2018504420A (ja) | 2015-02-06 | 2018-02-15 | マリナス ファーマシューティカルズ インコーポレイテッド | 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用 |
| DK3261640T3 (da) | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| CN104800168A (zh) | 2015-04-08 | 2015-07-29 | 石家庄四药有限公司 | 司替戊醇干混悬剂及其制备方法 |
| JP6668045B2 (ja) | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| WO2016205671A1 (en) | 2015-06-17 | 2016-12-22 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
| CA2989885C (en) | 2015-06-30 | 2025-05-06 | Neurad Ltd. | NEW RESPIRATION REGULATION MODULATION COMPOUNDS AND THEIR MANUFACTURING AND USE PROCESSES |
| ES2925951T3 (es) | 2015-07-22 | 2022-10-20 | John Hsu | Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso |
| KR102615486B1 (ko) | 2015-08-24 | 2023-12-19 | 조게닉스 인터내셔널 리미티드 | 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법 |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| US20220193082A1 (en) | 2015-09-14 | 2022-06-23 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| EP3170807B1 (en) | 2015-11-23 | 2019-12-11 | Frau Pharma S.r.l. | New method for synthesis of fenfluramine |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| WO2017122701A1 (ja) | 2016-01-14 | 2017-07-20 | 旭硝子株式会社 | フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品 |
| US11033550B2 (en) | 2016-03-28 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Medicament |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| US20190083425A1 (en) | 2016-08-24 | 2019-03-21 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht2b agonists and methods of using same |
| US20180092864A1 (en) | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
| KR20240110989A (ko) | 2017-02-08 | 2024-07-16 | 오비드 테라퓨틱스 인크. | 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들 |
| CA3062247A1 (en) | 2017-05-09 | 2018-11-15 | Zogenix International Limited | Methods of treating doose syndrome using fenfluramine |
| US20190125697A1 (en) | 2017-09-26 | 2019-05-02 | Zogenix International Limited | Method of reduction in convulsive seizure frequency |
| US20190247333A1 (en) | 2017-09-26 | 2019-08-15 | Zogenix International Limited | Method of reduction in convulsive seizure frequency |
| WO2019067413A1 (en) | 2017-09-26 | 2019-04-04 | Zogenix International Limited | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS |
| US20190091179A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| BR112020021324A2 (pt) | 2018-04-18 | 2021-01-19 | The Trustees Of Columbia University In The City Of New York | Terapia gênica para doenças causadas por pools de nucleotídeos em desequilíbrio incluindo síndromes de depleção do dna mitocondrial |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| US10517841B1 (en) | 2018-06-14 | 2019-12-31 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| WO2020014075A1 (en) | 2018-07-10 | 2020-01-16 | Zogenix International Limited | Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension |
| BR112021001135A2 (pt) | 2018-07-27 | 2021-04-20 | Xenon Pharmaceuticals Inc. | compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| EP3887481A4 (en) | 2018-11-30 | 2022-08-03 | Zogenix International Limited | METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS |
| WO2020176276A1 (en) | 2019-02-25 | 2020-09-03 | Zogenix International Limited | A formulation for improving seizure control |
| US20210299064A1 (en) | 2020-02-05 | 2021-09-30 | Zogenix International Limited | Method of treating patients with lennox-gastaut syndrome |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20220096514A1 (en) | 2020-09-29 | 2022-03-31 | Zogenix International Limited | Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine |
| WO2023034115A1 (en) | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| US20230165810A1 (en) | 2021-12-01 | 2023-06-01 | Zogenix International Limited | Fenfluramine for treatment of conditions associated with spreading depolarization |
-
2013
- 2013-05-03 US US13/887,014 patent/US9549909B2/en active Active
-
2014
- 2014-05-01 EP EP18152406.7A patent/EP3329909B1/en not_active Revoked
- 2014-05-01 PT PT147240378T patent/PT2991637T/pt unknown
- 2014-05-01 PT PT181524067T patent/PT3329909T/pt unknown
- 2014-05-01 EP EP14724037.8A patent/EP2991637B1/en not_active Revoked
- 2014-05-01 SI SI201431811T patent/SI3329909T1/sl unknown
- 2014-05-01 CA CA2909335A patent/CA2909335C/en active Active
- 2014-05-01 ES ES18152406T patent/ES2863929T3/es active Active
- 2014-05-01 HU HUE18152406A patent/HUE054577T2/hu unknown
- 2014-05-01 JP JP2016511083A patent/JP6441313B2/ja active Active
- 2014-05-01 PL PL14724037T patent/PL2991637T3/pl unknown
- 2014-05-01 BR BR112015027282A patent/BR112015027282A8/pt not_active Application Discontinuation
- 2014-05-01 WO PCT/EP2014/058954 patent/WO2014177676A1/en not_active Ceased
- 2014-05-01 DK DK14724037.8T patent/DK2991637T3/en active
- 2014-05-01 DK DK18152406.7T patent/DK3329909T3/da active
- 2014-05-01 LT LTEP18152406.7T patent/LT3329909T/lt unknown
- 2014-05-01 ES ES14724037.8T patent/ES2666657T3/es active Active
- 2014-05-01 PL PL18152406T patent/PL3329909T3/pl unknown
- 2014-05-01 AU AU2014261329A patent/AU2014261329B2/en active Active
- 2014-07-30 US US14/447,369 patent/US20140343044A1/en not_active Abandoned
- 2014-07-30 US US14/447,303 patent/US9603814B2/en active Active
- 2014-07-30 US US14/447,253 patent/US9610260B2/en active Active
- 2014-12-03 NO NO14819206A patent/NO3092234T3/no unknown
-
2016
- 2016-01-21 US US15/003,161 patent/US9603815B2/en active Active
-
2017
- 2017-02-10 US US15/429,641 patent/US20170151257A1/en not_active Abandoned
- 2017-02-10 US US15/429,646 patent/US10478442B2/en active Active
- 2017-02-10 US US15/429,506 patent/US20170151259A1/en not_active Abandoned
- 2017-02-10 US US15/429,516 patent/US10478441B2/en active Active
- 2017-02-10 US US15/429,650 patent/US20170151194A1/en not_active Abandoned
-
2018
- 2018-11-21 JP JP2018218149A patent/JP6655156B2/ja active Active
-
2019
- 2019-05-16 AU AU2019203448A patent/AU2019203448B2/en active Active
- 2019-05-31 AU AU2019203832A patent/AU2019203832B2/en active Active
- 2019-10-08 US US16/596,166 patent/US20200030341A1/en not_active Abandoned
-
2020
- 2020-01-31 JP JP2020014754A patent/JP6966584B2/ja active Active
- 2020-06-12 US US16/900,055 patent/US20210121479A1/en not_active Abandoned
- 2020-11-12 AU AU2020267264A patent/AU2020267264A1/en not_active Abandoned
-
2021
- 2021-05-21 HR HRP20210819TT patent/HRP20210819T1/hr unknown
- 2021-06-14 CY CY20211100530T patent/CY1124298T1/el unknown
-
2022
- 2022-02-08 US US17/667,136 patent/US12097206B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03389B (me) | Paraziticidne oralne veterinarske kompozicije које sadrže sistemski-delujuća aktivna sredstva, metodi i primene isтih | |
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| JP2011006431A5 (enExample) | ||
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| WO2013170068A3 (en) | Nuclear transport modulators and uses thereof | |
| BR112015023629A8 (pt) | Formulação de acetato de abiraterona | |
| LT3632919T (lt) | Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| EP2990405A4 (en) | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS WITH SUCH COMPOUNDS | |
| JP2012143233A5 (enExample) | ||
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| FR3000095B1 (fr) | Composition comprenant du 2,3,3,3-tetrafluoropropene et du 1,2-difluoroethylene | |
| JP2012126725A5 (enExample) | ||
| JP2014530840A5 (enExample) | ||
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| HRP20191348T1 (hr) | Aminosteroidi za liječenje bolesti povezanih s ptp1b | |
| JP2016530291A5 (enExample) | ||
| JP2015533163A5 (enExample) | ||
| CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| JP2010281322A5 (enExample) | ||
| EP2892554A4 (en) | HIV IMMUNOSTIMULATING COMPOSITIONS WITH RECOMBINANT EXPRESSED PILI ON BACTERIA AND CORRESPONDING METHODS | |
| CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. |